BPRMU191

BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation[1].

Product Specifications

CAS Number

[2131199-52-3]

UNSPSC

12352005

Target

Opioid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bprmu191.html

Smiles

O=C(C1=CC=C(N2C(CSC2C3=CC=C(C=C3)F)=O)C(C)=C1)O

Molecular Formula

C17H14FNO3S

Molecular Weight

331.36

References & Citations

[1]Huang YH, et al. Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia. Cell Chem Biol. 2024 Nov 21;31 (11) :1885-1898.e10.